Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). 17. Dezember 2020 Schimanski, C.C., Kasper, S., Hegewisch-Becker, S., Schröder, J., Overkamp, F., Kullmann, F., Bechstein, W.O., Vöhringer, M., Öllinger, R., Lordick, F., Heinemann, V., Geißler, M., Schulz-Abelius, A., Bernhard, H., Schön, M.R., Greil, R., Galle, P., Lang, H., Schmidtmann, I., Moehler, M., 2020. Oncoimmunology 9, 1806680. Abstract Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial Staehler M, Stöckle M, Christoph D C, Stenzl A, Potthoff K, Grimm M O, Klein D, Harde J, Brüning F, Goebell P J, Augustin M,… Weiterlesen Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. Welt, A., Wiesweg, M., Theurer, S., Abenhardt, W., Groschek, M., Müller, L., Schröder, J., Tewes, M., Chiabudini, M., Potthoff, K., Bankfalvi, A., Marschner, N., Schuler,… Weiterlesen